Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia

Authors Ian Hamilton-Craig, Karam Kostner, David Colquhoun, et al

Published 10 November 2010 Volume 2010:6 Pages 1023—1037

DOI http://dx.doi.org/10.2147/VHRM.S13496

Review by Single-blind

Peer reviewer comments 2

Ian Hamilton-Craig1, Karam Kostner2, David Colquhoun2, Stan Woodhouse2
1Griffith University School of Medicine, Southport, Queensland, Australia; 2University of Queensland, Brisbane, Queensland, Australia

Abstract: High-dose potent statin therapy in combination with ezetimibe is now standard practice for the treatment of adult patients with heterozygous familial hypercholesterolemia (heFH), as the result of numerous studies in patients with primary hypercholesterolemia or heFH. These studies have shown the combination to be both effective and safe in the short to medium term. Recently, short-term ezetimibe therapy has also been shown to be effective and safe in combination with statin therapy for children and adolescents with heFH. Effective statin–ezetimibe combination therapy is capable of achieving near-normal lipid profiles in heFH patients, with expected improvement in risk for cardiovascular disease (CVD) and improved life expectancy resulting predominantly from reduction in levels of low-density lipoprotein cholesterol. There are few data to support a pleiotropic action of ezetimibe with regard to CVD benefit, unlike therapy with statins. No serious and unexpected clinical adverse effects of combination statin–ezetimibe therapy have emerged till date, although data are limited in children and adolescents, for whom longer-term studies are required. Recent data suggesting possible proatherogenic effects of ezetimibe require confirmation. One large long-term randomized controlled clinical outcomes trial is in progress in non-FH patients to determine the efficacy and safety of ezetimibe therapy; it is unlikely that such a trial will ever be performed in patients with FH.

Keywords: familial hypercholesterolemia, ezetimibe, statin, combination therapy, low-density lipoprotein cholesterol

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 

 

Other article by this author:

Lipid-modifying therapy in the elderly

Hamilton-Craig I, Colquhoun D, Kostner K, Woodhouse S, d'Emden M

Vascular Health and Risk Management 2015, 11:251-263

Published Date: 14 May 2015

Readers of this article also read:

Patient perceptions on the subject of medical research

Ventolini G, Goodwin B, Woody C

Drug, Healthcare and Patient Safety 2014, 6:151-153

Published Date: 17 October 2014

Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy

Foody JM, Toth PP, Tomassini JE, Sajjan S, Ramey DR, Neff D, Tershakovec AM, Hu H, Tunceli K

Vascular Health and Risk Management 2013, 9:719-727

Published Date: 15 November 2013

Association between vitamin D and pressure ulcers in older ambulatory adults: results of a matched case–control study

Kalava UR, Cha SS, Takahashi PY

Clinical Interventions in Aging 2011, 6:213-219

Published Date: 2 August 2011

Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy

William Insull Jr, Peter P Toth, H Robert Superko, et al

Vascular Health and Risk Management 2010, 6:1065-1075

Published Date: 24 November 2010

Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update

Juan V Llau, Raquel Ferrandis, Pilar Sierra, et al

Vascular Health and Risk Management 2010, 6:855-867

Published Date: 29 September 2010

Benefits of statin therapy and compliance in high risk cardiovascular patients

Joel A Lardizabal, Prakash C Deedwania

Vascular Health and Risk Management 2010, 6:843-853

Published Date: 23 September 2010

Screening for type 2 diabetes in a multiethnic setting using known risk factors to identify those at high risk: a cross-sectional study

Laura J Gray, Jennifer R Tringham, Melanie J Davies, et al

Vascular Health and Risk Management 2010, 6:837-842

Published Date: 20 September 2010

Congestive heart failure in subjects with thyrotoxicosis in a black community

R C Anakwue, B J C Onwubere, B C Anisiuba, et al

Vascular Health and Risk Management 2010, 6:473-477

Published Date: 5 July 2010

Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India

Krishna K Sharma, Rajeev Gupta, Aachu Agrawal, et al

Vascular Health and Risk Management 2009, 5:1007-1014

Published Date: 20 November 2009